Canopy Growth is a money-losing marijuana start-up.
The company was recently forced to recapitalize its balance sheet even as it moves forward with an acquisition.
Canopy Growth (NASDAQ: CGC) is a high-risk investment. The stock has lost over 95% of its value since its initial public offering. There was material excitement around marijuana stocks and Canopy Growth a few years ago, but the company has not lived up to Wall Street's perhaps overzealous expectations. Now is probably not the time to jump aboard.
At one point in 2019, a share of Canopy Growth would have cost over $560 (after adjusting for reverse splits). Today, that same share would fetch a little over a buck. It has, basically, gone from being a Wall Street darling to being a penny stock. Penny stocks are high-risk investments that have a history of not working out well for shareholders.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks »
Image source: Getty Images.
A company doesn't find itself in penny stock land for no reason. One material problem for Canopy Growth is its history of losing money. In fact, after roughly a decade of being a public company, it still hasn't posted positive earnings. It's easy to understand why investors are tired of waiting around.
In late 2025, meanwhile, the company announced that it had recapitalized its balance sheet. That is a positive event for the company, but not a good thing from an investor's standpoint. Essentially, the company's financial condition was so weak that it had to cut deals with its bondholders. Notably, the company had to issue warrants as an enticement for the bondholders to play along. If those warrants are exercised, they will lead to shareholder dilution.
At the same time, the company is moving forward with its acquisition of MTL Cannabis. This, despite being a money-losing business that just had to recapitalize its balance sheet. Buying MTL Cannabis will strengthen Canopy Growth's position in the medical marijuana space. However, it is a cash-and-stock deal. So it puts more strain on Canopy Growth's balance sheet and will result in shareholder dilution.
It is entirely possible that Canopy Growth becomes a sustainably profitable business. In fact, it would be easy enough to focus only on the positive side of recent corporate events. But it is also possible that this money-losing penny stock is overextending itself. If that's the case, it could have trouble remaining a going concern. The risk-versus-reward profile for this marijuana stock is tilted too far toward risk for all but the most aggressive investors.
Before you buy stock in Canopy Growth, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Canopy Growth wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $424,262!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,163,635!*
Now, it’s worth noting Stock Advisor’s total average return is 904% — a market-crushing outperformance compared to 194% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of February 24, 2026.
Reuben Gregg Brewer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.